ABBV Abbvie Inc

$ABBV $BMY $SLS Part 5. 🤐 Bidding War is already happening behind the scenes with strict NDA’s signed for over 6 months now. ✌️🙏❤️‍🩹

$ABBV | ABBVIE INC. Q3 2026 EARNINGS HIGHLIGHTS ◆ EPS: $3.82 vs. $3.73 est. ✅ ◆ Revenue: $17.40B vs. $17.32B est. ✅ ◆ Net Income: $4.218B ◆ Operating Income: $6.267B (+229.2% YoY) ◆ R&D Expense: $2.567B (+10.7% YoY) ◆ SG&A Expense: $4.087B (+14.5% YoY) Segment Performance: ◆ Immunology: $9.165B (+16.3% YoY) ◆ Neuroscience: $3.389B (+19.4% YoY) ◆ Oncology: $1.696B (+0.8% YoY) ◆ Aesthetics: $1.176B (-1.4% YoY) Key Metrics: ◆ Skyrizi global net revenues grew 22.7% YoY to $5.776B in Q3 2026, driven by strong U.S. and international demand. ◆ Humira global revenues declined 31.2% YoY to $683M, continuing biosimilar erosion post-patent-cliff. ◆ Quarterly dividend raised 5.2% to $1.82 per share, payable February 16, 2027; dividend up 355% since AbbVie's 2013 inception. Forward Guidance: ◆ FY2026 adjusted diluted EPS guidance raised to $13.95-$13.99 (from $13.76-$13.96), including $0.69/share IPR&D headwind through Q3. ◆ Guidance excludes any acquired IPR&D and milestones expense that may be incurred beyond Q3 2026, as those cannot be reliably forecasted.

Just like yesterday, the stocks making new 52-week relative strength high vs the S&P 500 are defensive healthcare and consumer staples stocks like $ABBV $BIIB $KO etc.

$ABBV: a 2022 study cited in Garcia found delayed-onset nodules with Juvederm at 0.5% to 0.98%, higher than other fillers. Plaintiffs allege the word granuloma appears nowhere in its warnings. Nothing to claim. Open Class Actions.

$ABBV FDA approved subcutaneous induction for SKYRIZI in Crohn's disease on Friday, so patients can now start at home with the on-body injector instead of an infusion center. Same device carries them through maintenance every 8 weeks. In the Phase 3 AFFIRM study, 56% hit clinical remission at week 12 vs 30% on placebo, and endoscopic response was 43% vs 15%. Among patients new to advanced therapy it was 74% vs 27%, and 65% of the study population had already failed an advanced therapy.

$ABBV Regardless if we are in a recession or not people are always going to get sick and medicine is going to be needed around the world 🌏🌎🌍 we are still early with $ABBV

$ABBV $KURA $SNDX This is a hematologist prescriber survey embedded within the recent SNDX note, focused on NPM1 mutant AML (the largest subset of adult AML, ~30% of all AML). Core survey findings 1. Diagnosis & testing behavior Virtually all responding leukemia specialists now routinely test newly diagnosed AML patients for NPM1 mutation at baseline. Previously, many viewed revumenib only as a KMT2Ar drug; survey shows this perception has shifted after NPM1 label approval + real-world data. 2. Treatment preference for R/R NPM1 AML (already approved setting) ◦ Efficacy / deep MRD response is the #1 decision factor (ranked far above safety, oral convenience, or price). ◦ HCPs say revumenib’s ability to drive MRD negativity is its biggest differentiator vs older salvage regimens. ◦ Survey uptake expectation: Respondents expect Revuforj to capture a dominant share of eligible R/R NPM1 patients, even with competing menin inhibitor now on market.

$ABBV reported before the open this morning. Adjusted EPS of $3.82 beat the $3.73 analyst estimate by 2.4%, according to Stock Meadow. Revenue was $17.4B versus $17.3B expected.

$ABBV: AbbVie's own premarket testing is in the Juvederm complaint: 65% to 68% of subjects had lumps or bumps, 11% to 22% nodules, yet plaintiffs allege granuloma risk went unwarned. Nothing to claim. Open Class Actions.

$ABBV | AbbVie Q3 2026 Earnings - Q3 Adj EPS: $3.82 (est $3.74) - Skyrizi Rev: $5.78B (est $5.74B) - Net Rev: $17.40B (est $17.34B) - Imbruvica Rev: $522M (est $527.3M) - Rinvoq Rev: $2.71B (est $2.7B) - Sees FY Adj EPS: $13.95 To $13.99 (prev guidance $13.76 To $13.96)

$ABBV: one word is missing in Garcia: granuloma appears nowhere in Juvederm's warnings, glossary or website, the complaint alleges, even though the lumps can surface years later. Nothing to claim. Open Class Actions.

The Nasdaq dropped 1.9% yesterday. $ABBV closed at a record high. This morning it pushed through 285.40, tagging 290.56. Now the job is holding above 285.40 into the close. That's what I'm watching.

$ABBV I’ve just stubbornly held this since the spin out in 2013 collecting dividends and capital appreciation the entire way instead of trying to trade it like the day flippers and hedge funds. A good lesson for the kids out there!

$ABBV I at least added this yesterday, 274.94 ath. But made more mistakes yesterday than any day the last three months. So many false breakouts.

$ABBV What a monster stock this has been ... now consolidating over the base for potential next leg up

$ABBV definitely over 300 tomorrow. Congratulations to all the long-term holders. He believed in this company and still do! 

$ABBV AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease

$ABBV 🏥 The U.S. FDA approved a subcutaneous induction regimen for AbbVie's SKYRIZI (risankizumab-rzaa) in adults with moderately to severely active Crohn's disease, expanding administration options with an on-body injector.

$ABBV Mrch 320c, good entry point, but be sure to know ER is coming so dont go heavy, ER can do what it did to $JNJ and then pump again

$ABBV NOV20 300C · still actionable Zone: $285.40 to $289.40 Invalidation: close under $282.15 Objectives: $291.40, then $300 The math: up 1.4% to the first objective and 4.4% to the second, against 1.8% risk on the invalidation, better than 2 to 1 to the second. Dear friend, think of a runner who was already close to the front and then got good news at breakfast. AbbVie closed at 284.80 dollars on Wednesday and was trading near 287.40 dollars before the bell today after its lutikizumab study met its main goal in Phase 3, and that matters because buyers now have a fresh reason to press price toward the 291.40 dollar high with earnings on October 30 still ahead. This is a swing setup built on strength holding above the 282.15 dollar low from Wednesday, where sellers tried and failed to push it lower. P.S. Watch the 291.40 dollar high today, friend. A close above it would put the round 300 dollar line in plain sight.